Susquehanna Fundamental Investments LLC Takes $5.26 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Susquehanna Fundamental Investments LLC bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 91,886 shares of the biotechnology company’s stock, valued at approximately $5,258,000.

A number of other institutional investors have also made changes to their positions in the business. Thornburg Investment Management Inc. raised its stake in BioMarin Pharmaceutical by 305.9% in the 2nd quarter. Thornburg Investment Management Inc. now owns 43,061 shares of the biotechnology company’s stock valued at $2,464,000 after acquiring an additional 32,453 shares during the period. Greenwood Capital Associates LLC bought a new position in BioMarin Pharmaceutical during the second quarter worth $320,000. Van ECK Associates Corp boosted its position in BioMarin Pharmaceutical by 68.8% during the second quarter. Van ECK Associates Corp now owns 307,103 shares of the biotechnology company’s stock worth $17,572,000 after purchasing an additional 125,221 shares during the period. Hsbc Holdings PLC increased its holdings in shares of BioMarin Pharmaceutical by 107.5% in the second quarter. Hsbc Holdings PLC now owns 307,543 shares of the biotechnology company’s stock valued at $17,640,000 after purchasing an additional 159,361 shares during the last quarter. Finally, Palo Alto Investors LP acquired a new position in shares of BioMarin Pharmaceutical in the second quarter valued at $39,068,500. 98.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Trading Up 0.9%

Shares of BioMarin Pharmaceutical stock opened at $65.23 on Tuesday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The firm has a 50-day moving average of $61.88 and a 200-day moving average of $58.19. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98. The stock has a market cap of $12.63 billion, a PE ratio of 176.30, a PEG ratio of 0.46 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The business had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. During the same period last year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical’s revenue for the quarter was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. As a group, sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current year.

Key Stories Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: The agreement removes a significant legal and competitive overhang for BioMarin and provides for royalty payments on Yuviwel sales in the U.S., European Union, Brazil and South Korea. Investors viewed the resolution as a potentially valuable new revenue stream while reducing litigation uncertainty. BioMarin Announces Global Settlement With Ascendis Pharma
• Positive Sentiment: Jefferies raised its price target on BMRN from $104 to $105 and reiterated a “buy” rating, implying substantial potential upside based on the firm’s valuation. Jefferies Raises BioMarin Price Target
• Neutral Sentiment: Market coverage characterized the patent settlement as a clean removal of an overhang, but analysts broadly kept their existing ratings unchanged, suggesting the news improves visibility without yet prompting a major reassessment of BioMarin’s outlook. Street Commentary on BioMarin and Ascendis
• Negative Sentiment: HC Wainwright raised its target only modestly, from $59 to $60, while maintaining a “neutral” rating. The target remains below the prevailing share price, highlighting valuation concerns and the possibility that some settlement benefits are already reflected in BMRN. HC Wainwright Raises BioMarin Price Target

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BMRN. Royal Bank Of Canada cut their target price on shares of BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research note on Tuesday, July 7th. Sanford C. Bernstein decreased their price target on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 5th. Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. UBS Group set a $88.00 price objective on shares of BioMarin Pharmaceutical in a research report on Wednesday, August 26th. Finally, Oppenheimer upped their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus price target of $88.92.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.